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ABSTRACT Chagas disease (CD) is recognized as one of the major neglected global
tropical diseases. Benznidazole (BNZ) is the drug of choice for the treatment of
adults, young infants, and newborns with CD. However, the pharmacokinetics (PK) of
BNZ have been poorly evaluated in all age groups, with consequent gaps in knowl-
edge about PK-pharmacodynamic relationships in CD. The purpose of this study was
to develop and validate a bioanalytical method to quantify BNZ levels in small-
volume whole-blood samples collected as dried blood spots (DBS). The analysis was
performed using high-performance liquid chromatography-positive electrospray tan-
dem mass spectrometry. PK evaluation in healthy male volunteers was conducted to
verify the correlation between DBS and plasma BNZ concentrations. The calibration
curve was linear from 50 to 20,000 ng · ml1. Intra- and interday precision and bias
values were less than 14.87% (n  9) and 9.81% (n  27), respectively. The recovery
rates ranged from 94 to 100% with no matrix effect. There was no hematocrit level
effect in a range of 20 to 70%. The PK results obtained from DBS and plasma were
comparable (r2  0.8295) and equivalent to previously published information on
BNZ. BNZ in DBS was stable at room temperature for more than one year. This arti-
cle describes the first microsampling method for measuring BNZ levels in DBS that
has the potential to facilitate broad implementation of PK in clinical trials involving
adult and pediatric patients in remote areas and helps to address existing knowl-
edge gaps in the treatment of CD.
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Chagas disease (CD) is recognized by the World Health Organization (WHO) as oneof the major neglected global tropical diseases. CD remains a significant public
health problem, with social and economic impacts in several countries in Latin America,
where it is endemic, affecting about 6 million people (1). In addition, CD is increasing
in developed countries where it is not endemic due to globalization and population
flow (2).
Presently, there are only two drugs available with proven clinical efficacy against
Trypanosoma cruzi: benznidazole (BNZ) and nifurtimox, launched in the early 1970s (3).
BNZ is widely accepted as the drug of choice for acute and early chronic-phase Chagas
disease due to the large body of evidence from adequate and well-controlled studies
(4). Safety and tolerability issues (such as hypersensitivity reactions, allergic dermopa-
thy, and painful peripheral neuropathy) (5–7), as well as the long treatment duration,
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have limited broader use of the current compounds, particularly in the adult popula-
tion, but these treatments have been shown to be manageable when used at a
recommended dose of 5 mg/kg of body weight/day (8).
After a long period with limited information about pharmacokinetic (PK) parameters
for BNZ (8, 9), various studies in patients and healthy volunteers have now been
published. In a recent systematic review and meta-analysis, PK parameters were
reported with a high degree of consistency across nine studies (2). PK values in healthy
volunteers were different for men and women after oral administration of 100-mg
tablets (8). Pediatric population PK was assessed in one clinical study, which showed
lower BZN concentrations than those reported in adults, as well as fewer adverse events
(10). However, until now, there has been no published data on PK in neonates and
children under 2 years of age (10).
PK parameters are assessed using bioanalytical methods for the quantification of drugs
in a biological matrix obtained by sampling in a clinical setting. There are a few methods
reported in the literature for BNZ quantification in different matrices (tissues, plasma, serum,
urine, and milk), notably differential pulse polarography high-performance liquid chroma-
tography (HPLC) with ultraviolet detection (4, 11, 12), ultrahigh-performance liquid chro-
matography (UHPLC) with ultraviolet detection (13), and liquid chromatography coupled
with tandem mass spectrometry (LC-MS/MS) (5, 14).
CD is most commonly diagnosed in poor regions with limited laboratory infrastruc-
ture and a lack of basic technologies for local bioanalytical testing. A noninvasive
sampling method, allowing easy collection, storage, and transport of stable samples, is
an important tool for conducting clinical trials in these settings, in particular those
involving pediatric patients (15).
Over recent years, many reports have described the use of dried blood spots (DBS)
(i.e., blood samples dried on a collection card) for quantification of drugs (15–21). DBS
samples are commonly obtained from a finger prick using an automatic lancet on a
specimen collection card. DBS sample collection is much easier and involves smaller
sampling volumes than performing a venipuncture, and with proper training patients
may even collect the samples themselves at home (20). Microsampling is often the
preferred technique for pediatric PK studies (21).
The objectives of this study were to develop a DBS-based microsampling method for
the quantification of BNZ in human blood for pharmacokinetic studies and to establish
a new tool for PK assessment in patients with CD.
RESULTS
Selectivity, carryover, and cross talk. The method used demonstrated excellent
chromatographic selectivity, with no endogenous or metabolite interference at the
retention times for both BNZ and the internal standard (IS) in six different sources of
whole blood (one from postprandial collection) and in the presence of local anesthetic
drugs. No residual chromatographic peak after ULOQ (upper limit of quantification)
injection was observed after carryover evaluation. Even with good resolution (2.4)
between the BNZ and IS chromatographic peaks, cross talk was evaluated and no
interference between multiple reaction monitoring (MRM) channels was observed. For
all tests, the response for blank DBS samples was within the required 20% of the
average response of the lower limit of quantification (LLOQ) and 5% of the IS peak area.
ME. The matrix effect (ME), recovery efficiency (REC), and process efficiency (PE)
were consistent over the tested concentration ranges for analyte low quality control
(LQC) (67%, 109%, and 73%, respectively) and high quality control (HQC) (58%, 111%,
and 71%, respectively).
The recovery results according to the FDA guidelines were 109%, 98%, and 111% for
LQC, medium quality control (MQC), and HQC, respectively. The means from the QC
samples was 106%  7%. IS has a recovery of 111%. The matrix factor (MF) values
according to European Medicines Agency (EMA) guidance were 0.67 and 0.58 for LQC
and HQC, respectively. The values found for normalized matrix factor (NMF) according
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to Brazilian Health Surveillance Agency (ANVISA) guidance were 0.98  0.07 for LQC
and 1.10  0.03 for HQC. The value between two quality control levels was 1.04  0.08.
Linearity and sensitivity. A calibration curve was constructed using eleven con-
centrations covering a range (50 to 20,000 ng · ml1) derived from the peak area ratio
of BNZ to IS. Weighted-least-square (WLS) linear regression, determined using 1/x2, was
used to obtain linearity over four orders of magnitude, with a mean determination
coefficient of 0.9840 (n  3) and accuracy of back-calculated results of between 94.93
and 106.47%, as shown in Table 1. The lowest concentration at which BNZ could be
quantified with an acceptable accuracy and precision was 50 ng · ml1 (LLOQ).
Precision and accuracy. The results for intra-assay and interassay precision and
accuracy for the quality control samples at concentration levels of 50, 150, 10,000, and
17,000 ng · ml1 for BNZ are summarized in Table 2. The intra-assay precision relative
standard deviation (RSD; in percent) varied from 0.77 to 11.26%, and accuracy (percent
deviation from nominal concentration) was 0.65 to 14.87%. The interassay precision
RSD for samples at the LLOQ was 7.84%, and the interassay accuracy was 7.97%.
Stability evaluation. The results indicated that BNZ was stable under experiment
conditions. Table 3 describes the back calculation and comparison with the nominal
value.
TABLE 1 Precision and accuracy of concentration levels of calibration curve
Spiked concn
(ng · ml1)
Determined concn (ng · ml1)





50 47.994  6.883 14.34 4.01
100 101.828  4.798 4.71 1.83
400 413.372  32.867 7.95 3.34
800 812.695  92.314 11.36 1.59
1,500 1,517.816  7.750 7.75 1.19
3,500 3,674.722  268.634 7.31 4.99
5,000 4,905.165  483.027 9.85 1.90
8,000 8,517.975  343.651 4.03 6.47
12,000 12,256.665  412.010 3.36 2.14
16,000 15,189.454  549.700 3.62 5.07
20,000 19,343.436  942.394 4.87 3.28
TABLE 2 Intra-assay and interassay imprecision of BNZ measurements on DBS
Nominal concn (g · ml1) Found mean concn (g · ml1) SD (g · ml1) RSD (%) RE (%)
Intra-assay (n  9)
0.05
Day 1 0.053 0.003 5.30 6.05
Day 2 0.053 0.002 4.00 6.67
Day 3 0.056 0.006 11.26 11.20
0.15
Day 1 0.165 0.008 4.75 10.10
Day 2 0.157 0.013 8.42 4.46
Day 3 0.172 0.006 3.71 14.87
10.00
Day 1 10.197 0.382 3.75 1.97
Day 2 10.099 0.386 3.82 0.99
Day 3 11.157 0.169 1.51 11.57
17.00
Day 1 18.142 0.736 4.05 6.72
Day 2 16.890 0.525 3.11 0.65
Day 3 17.832 0.138 0.77 4.89
Interassay (n  27)
0.05 0.054 0.004 7,84 7.97
0.15 0.165 0.011 6.92 9.81
10.00 10.485 0.579 5.53 4.84
17.00 17.621 0.747 4.24 3.65
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Dried blood spot issues. The results show no significant influence of percent
hematocrit on the precision and accuracy of the quantification of BZN (Fig. 1). The
postcolumn infusion shows no matrix interference at the retention time of BNZ and IS
at any hematocrit level (data not shown). The whole-blood-spot approach gives
acceptable precision and accuracy results for all quality control levels, including LLOQ.
Pharmacokinetic evaluation. The results of PK parameters for DBS and plasma
samples obtained from healthy volunteers are described in Table 4, including the
DBS/plasma ratio for all parameters. The calculated area under the concentration-time
curve from 0 h to time t (AUC0-t)/AUC0-∞ ratios were 0.79 and 0.92 for DBS and plasma,
respectively. Hematocrit levels for volunteers were in the normal range (42.2, 45.3, and
43.5%).
The calculated DBS concentration show a good degree of correlation with plasma
concentrations, as described by r  0.9108 (P  0.0001; 95% confidence interval [CI],
0.08366 to 0.9521), but with significant negative bias for concentrations higher than
1,000 ng · ml1.
The Passing-Bablok regression between paired BNZ-DBS and plasma concentration
is plotted and Bland-Altman analysis are shown in Fig. 2. The slope of the regression
line (Fig. 2A) was 0.84 (95% CI, 0.72 to 0.97), with an intercept of – 8.72 (95% CI, 144.44
to 92.03). The Cusum test for linearity showed no significant deviation from linearity
(P  0.15). The Bland-Altman (Fig. 2B) plot shows a relative difference between DBS and
plasma concentration of 20.9%  30%, with high bias for samples under 400
ng · ml1.





concn (g · ml1) SD (g · ml1) RSD (%) RE
Benchtop 0.15 0.149 0.006 4.28 0.38
17.00 17.530 303.911 1.73 3.12
Autosampler 0.15 0.147 0.023 15.64 2.83
17.00 15.884 449.986 2.28 6.56
Storagea 0.15 0.143 0.008 6.14 4.35
17.00 15.423 292.278 1.90 9.28
Storageb 0.15 0.153 0.016 10.23 2.22
17.00 18.200 1.420 7.80 7.06
Storagec 0.15 0.159 0.012 7.42 6.06
17.00 18.046 1.011 5.60 6.15
aStorage lasted for 466 days at temperatures between 23°C and 26°C.
bStorage lasted for 7 days at 40°C.
cStorage lasted for 3 days at 40°C.
FIG 1 Hematocrit effect at 20%, 30%, 40%, 50%, 60%, and 70% in LQC and HQC samples.
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The results of bioequivalence evaluation (46 volunteers finished the clinical study)
showed maximum concentration of drug in serum (Cmax) of 2.53 and 2.48 g · ml1 and
AUClast of 50.22 and 48.93 h · g · ml1 for Radanil and LAFPE formulations of BNZ,
respectively, and confidence intervals of 0.84 to 1.13 and 0.81 to 1.16 for Cmax and
AUClast, respectively (individual patient data are presented in the supplemental mate-
rial). Formal comparison shows that these values meet the standard criteria for bio-
equivalence.
DISCUSSION
To the best of our knowledge, this is the first report of a DBS–LC-electrospray
ionization (ESI)-MS/MS bioanalytical method for determination of BNZ in whole-blood
samples. A BNZ DBS assay was developed in combination with a fast, accurate, precise,
and reproducible LC-ESI-MS/MS application. The assay was validated based on criteria
described by FDA guidelines for bioanalytical method validation (22), taking into
consideration the issues specific to DBS. In this method, the sampling procedure was
simplified and requires significantly lower volumes of blood. In addition, the DBS can
easily be stored and transported with a high degree of stability (23).
The mass spectrometer was set up to obtain the maximum signal without fragmen-
tation in the ionization source and an MRM with the most sensitive and stable fragment
to obtain a high signal/noise ratio (24). The chromatographic parameters were opti-
mized to obtain separation (resolution, 1.5) between the analyte and IS with a good
shape peak (tailing factor, 1.2), good run time (5.0), and minimum matrix effect
associated with the sample preparation technique.





(mean  SD, n  3)
Plasma
(mean  SD, n  3)
Cmax (g · ml1) 2.070  0.479 1.937  0.225 1.07 0.4729
Tmax (h) 2.83  1.16 2.67  1.44 1.06 0.4226
kel (h1) 0.041  0.017 0.056  0.008 0.74 0.2458
t1/2 (h) 19.38  9.94 12.62  1.80 1.54 0.3478
AUC0-t (g · ml1 · h1) 26.623  2.880 32.838  5.116 0.81 0.0617
AUC0–∞ (g · ml1 · h1) 33.691  7.889 35.885  6.499 0.94 0.7007
aP values were determined by two-tailed, paired t test, with 99% confidence intervals (GraphPad Prism,
v. 5.03).
FIG 2 (A) Plot of BNZ concentration in DBS against BNZ concentration in plasma. The solid line is the line of true identity. (B) Bland-Altman plot for total plasma
and DBS. The dotted lines indicate the 95% limits of agreement, and the solid line indicates the mean ratio bias.
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The LC-MS/MS methods described in the literature give the results of an analytical
run of 5.0 min with a large volume of biological matrix (2.5 ml urine) and a high volume
of organic extraction solvent (2.5 ml dichloromethane), for a linear range from 10 to
50,000 ng · ml1 (14), and an analytical run of 3.0 min with a small volume of biological
matrix (50 l serum) and a small volume of organic extraction solvent (250 l of ethyl
acetate), for a linear range from 100 to 3,000 ng · ml1 (8). The method described in this
article uses whole blood as the biological matrix at small volumes, a 5.0-min analytical
run, and 1.7 ml dichloromethane in the extraction procedure, with a linear range of 50
to 20,000 ng · ml1.
Differences were documented in the results of the matrix effect according to the
EMA approach (with MF [see equation 4] at the same value of ME [see equation 1]) and
the results according to the ANVISA approach (data from C samples are different for
equation 3 [C/A  100]). These findings are explained by the presence of the IS area
ratio (see equation 5). Even with a nonstable isotope label (SIL), no influence of matrix
for BNZ and IS was observed. The recovery of IS was 111% with no statistical difference,
and recovery of BNZ was 106% (difference, 5.333  3.767; P  0.1803). According to
the ANVISA approach, the percent coefficient of variation of the NMF should not be
more than 15% in order to demonstrate the absence of any matrix effect. No limits for
acceptance are described, but a range of 0.8 to 1.20 is commonly used (25). No
significant signal suppression was observed. Accordingly, qualitative results after
postextraction infusion demonstrates that the matrix effect is the same for the range of
hematocrit levels studied for BNZ and IS analysis (20 to 70%).
Different hematocrit levels often lead to a diverse spread of blood onto the spot of
the collection card, consequently the use of a center punch may result in the transfer
of different blood volumes to sample preparation tubes. The current assay procedures
involved the use of a whole-spot punch to avoid this effect (26); indeed, no influence
of hematocrit levels was observed for the samples analyzed by this method, even with
different levels of blood spread between the samples (27). The whole-spot approach
with a fixed volume transferred by pipette can be considered a useful alternative that
avoids hematocrit issues (15).
The method showed selectivity, linearity, precision, and accuracy, no matrix effect,
no carryover, and stability of samples. In addition, potential DBS issues were avoided by
the use of a fixed volume of blood and whole-spot analysis. Documented stability over
a period of greater than 12 months at room temperature (between 20°C and 26°C)
and stability over 7 days at 40°C with relative humidity of 53% is an important
requirement for the application of this sampling method in remote regions where CD
is endemic. The stability over the course of one week is important to guarantee sample
integrity between blood collection and transport to a specialized laboratory and referral
centers.
To the best of our knowledge, no similar study was reported in the literature to
compare DBS sampling concentrations with plasma concentrations of BNZ. Although
there was no significant deviation from linearity, we can see trends for underestimation
of concentrations above 1,000 ng · ml1 with the DBS method that contribute to high
CI intervals for the intercept and for a high range of differences between sampling
methods, as shown by Bland-Altman analysis, in addition to high variability, as samples
under 400 ng · ml1 showed results that were correlated as well as nonconcordant
measures. For most clinical studies, this finding may have limited impact, as a single
method is likely to be used. However, it is important to highlight this phenomenon
when pooling or discussing data from different pharmacokinetic studies. Complemen-
tary evaluation of the relevance of this finding in patient samples also may be useful,
as will be further analyses of DBS samples from venous and capillary collection.
Of note, a comparison of results from the 46 volunteers and those obtained by J.
Raaflaub and W. H. Ziegler for the Radanil formulation of BNZ shows bioequivalence,
with similar bioavailability after a single oral dose of 100-mg tablets. This is the only
published information comparing the bioavailability of Brazilian BZN formulations to
the older Roche products.
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In resource-limited settings, with limited laboratory infrastructure and a lack of basic
technologies for local bioanalytical testing, a noninvasive sampling method, allowing
easy collection, storage, and less expensive transport of stable samples, is an important
tool for conducting clinical trials, in particular those involving pediatric patients.
Conclusions. We have described a simple and rapid LC-MS/MS method for the
quantification of BNZ with a DBS sampling technique, which showed selectivity and an
acceptable level of precision and accuracy and adequate sensitivity and stability. This
method was successfully applied to a clinical PK study of BNZ (100-mg tablets) in
healthy male volunteers. A positive correlation with plasma concentration indicates
that this method could be applied in adult and pediatric trials, thereby simplifying the
conduct of PK studies in remote areas where CD is endemic and where only limited
clinical and laboratory infrastructure is available. Additional studies at high temperature
and high humidity settings would be useful to complement the current evaluation.
Complementary evaluation of DBS in patients in the acute phase of infection and of the
correlation of venous puncture and peripheral sampling method in diverse disease
phases should be conducted.
MATERIALS AND METHODS
Chemicals and reagents. One hundred-mg BNZ tablets and BNZ standard (99.47% purity; Nortec
Química) were obtained from the Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE; Recife,
Brazil), and the internal standard (IS) citalopram hydrobromide was obtained from United States
Standards (Rockville, MD).
All solvents used were HPLC grade. Ultrapure water was obtained from Milli-Q (Millipore Corporation,
MA, USA). Formic acid (E. Merck, Darmstadt, Germany), acetonitrile (ACN), and isopropanol were supplied
by J. T. Baker (Phillipsburg, NJ, USA), and dichloromethane (DCM) was supplied by Mallinckrodt
Chemicals (Phillipsburg, NJ, USA).
Preparation of stock and work solutions. Two sets of stock solutions of BNZ were prepared in
acetonitrile from two independent weighings at a target concentration of 1 mg · ml1 free base. One
stock solution was used to prepare calibration standards and the other to prepare QC samples. Stock
solutions were further diluted with purified water to obtain separate working solutions in a range of 0.5
to 200 g · ml1 BNZ.
For the preparation of QC samples, separate working solutions were prepared with purified water at
three concentrations: LLOQ, LQC, MQC, and HQC for BNZ (0.5, 1.5, 100, and 170 g · ml1, respectively).
Stock solutions of IS prepared in acetonitrile at a target of 10 g · ml1 free base were stored at
20°C until use. Stock solutions were further diluted with 1% formic acid in dichloromethane to a
concentration of 3.3 g · ml1 (extract solution). Fresh extract solutions were prepared before each run.
Preparation of calibration standards and QC samples in dried blood spots. Calibration standards
were freshly prepared from the whole-blood working solutions (human blood with EDTA as anticoag-
ulant) to obtain BNZ in a calibration range of 50 (LLOQ) to 20,000 (ULOQ) ng · ml1. Calibration standards
were spotted on Whatman 903 filter paper cards by transferring 50 l onto the card with a volumetric
pipette. Thereafter, the blood spots were left to dry for a minimum of 3 h at room temperature. Quality
control samples were prepared according to the calibration curve to obtain LLOQ (50 ng · ml1), LQC (150
ng · ml1), MQC (10,000 ng · ml1), and HQC (17,000 ng · ml1). Fresh calibration standards and QC
samples were prepared before each run.
Sample extraction. Each DBS sample was punched into a vial with a standardized manual punch (13
mm) to obtain a whole-spot disk that was then extracted with 1,700 l extraction solution (1% formic
acid in dichloromethane) containing the internal standard, citalopram (3.3 g · ml1). Extraction was
performed with a vortex for 30 min at room temperature (approximately 22°C). The supernatant (organic
phase) was transferred to a clean tube and evaporated to dryness under a stream of nitrogen at 40°C in
a nitrogen evaporator. The residue was reconstituted in 250 l acetonitrile-water (1:1), and 150 l was
transferred to vials.
LC-MS/MS method development. The samples were measured using a Prominence analytical HPLC
(Shimadzu, Kyoto, Japan) coupled to a Sciex 3200 QTRAP (SCIEX, Toronto, Canada) equipped with a
Turbo IonSpray source and quadrupole analyzer. Infusion experiments were performed for multiple
reaction monitoring (MRM) optimizations with a Harvard Apparatus 11 elite syringe pump (Hollston, MA)
at a flow rate of 10 l · min1.
An MRM method was prepared that included the most intense transitions for BNZ and the internal
standard. Figure 3 shows BNZ positive ion electrospray mass spectra with the precursor and most intense
product ions (m/z 261.1  91.3) and the mass transition, monitored in MRM mode, for IS. No fragmen-
tation at the ionization source was observed by full scan monitoring.
The mass spectrometric parameters (cone voltage, collision energy, source temperature, desolvation
gas, and multiplier detection) were optimized to obtain maximum sensitivity at unit resolution. The ESI
was positive, capillary voltage was set to 5.5 kV, and heated turbo gas (air) was used with a flow rate of
45.0 liters · min1 at 400°C. The following transitions were monitored in MRM mode: m/z 261.1  91.3
(quantifier) for BNZ and m/z 325.2  109.0 (quantifier) for IS. Optimal CXP (collision cell exit potential)
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was found to be 4 V for both BNZ and IS. The declustering potential (DP) applied was 41 V and 51 V for
BNZ and IS, respectively. Collision energy (CE) was 41 V for BNZ and 37 V for IS.
Quantitation experiments were performed using a 20A LC system (Shimadzu Corporation, Kyoto,
Japan) equipped with two analytical pumps (LC-20AD), a vacuum degasser (DGU-20A3), an autosampler
(SIL-20AC HT), and a controller module (CBM 20A). The chromatographic column used was a Gemini NX
(C18; 4.6 mm by 150 mm; 5 m; Phenomenex, CA, USA), operating at 1.0 ml · min1 for a total running
time of 5 min. Isocratic elution was achieved using mobile phase A (water plus 0.1% formic acid) and
mobile phase B (acetonitrile plus 0.1% formic acid) (43:57, vol/vol). The retention time was 2.9 min for
BNZ and 1.3 min for IS with a total run time of 5 min. The peak asymmetry was 0.94 and 1.12 for BNZ
and IS, respectively, and there was a resolution of 2.4 between peaks.
The eluent from the column was directed to the Turbo IonSpray probe without split ratio. Thirty
microliters of the extracted sample was injected for the LC–MS/MS experiments, followed by a 0.8-ml strong
needle wash consisting of 0.5% formic acid in acetonitrile–2-propanol–water (45:10:45, vol/vol/vol). Before
analysis, samples were kept in an autosampler at 4°C. Reference chromatograms are shown in Fig. 4.
System control and data acquisition were performed with Analyst 1.5.2 software, including the
Explore option (for chromatographic and spectral interpretation) and the Quantitate option (for quan-
titative information generation). Calibration curves were constructed with the Analyst Quantitation
program with a linear WLS regression using 1/xx.
Validation procedure. Validation was carried out according to FDA guidelines for bioanalytical
assays (22). There are particular issues for the validation of DBS methods, including the need for the
evaluation of spot volume, punch location, and influence of hematocrit levels (28). In order to set up and
validate the method, whole blood from healthy adult donors was spiked with BNZ at different concen-
trations. Fifty l of each spiked blood sample was spotted on Whatman 903 filter paper and used for the
calibration curve.
Selectivity, carryover, and cross talk. To evaluate the selectivity of the method, blank human
whole-blood samples from five donors (human blood with EDTA as an anticoagulant) and from one
postprandial donor were transferred to DBS and analyzed with a running time of 15 min (3-fold, as
described above) for determining whether blood components interfere with the detection of the
compounds of interest. For the evaluation of the interference between prilocaine and lidocaine (drugs
commonly used as local anesthetics for sample collection in pediatric clinical trials), blank human blood
samples were spiked with these compounds at a concentration of 1,000 ng · ml1.
Carryover effect was evaluated by analysis of blank samples before and after injection of extracted
samples at 17,000 ng · ml1 and compared to an LLOQ response.
Cross talk interference was also evaluated by injection of nonextracted solutions (matrix free) of BNZ
(17,000 ng · ml1) and IS (2,000 ng · ml1) separately.
Matrix effect. The recovery was assessed according to the guidance for industry bioanalytical
method validation (18). The BNZ and IS recoveries were compared by unpaired t test (95% CI) (GraphPad
Prism, version 5.00 for Windows; GraphPad Software, San Diego, CA USA, www.graphpad.com). For
calculation of extraction efficiency, equation 3 was applied at three concentrations (LQC, MQC, and HQC).
In addition, the matrix effect (ME), recovery efficiency (REC), and process efficiency (PE) were also
evaluated at LQC and HQC concentrations according to the following equations (29):
ME%  B ⁄ A  100 (1)
REC%  C ⁄ B  100 (2)
PE%  C ⁄ A  100 (3)
A is defined as the peak area of neat quality control samples prepared in acetonitrile, B is the DBS
blank extracted and then spiked with BNZ in acetonitrile, and C is DBS spiked with BNZ and extracted.
To evaluate the influence of the matrix in bioanalytical response, two additional approaches were
used. The matrix factor (MF) was obtained for two concentrations (LQC and HQC), according to European
guidelines (30), by calculating the ratio of the peak area in the presence of matrix (B) to the peak area
in absence of matrix (A) per the following equation:
FIG 3 MS/MS product ion scans of BNZ, obtained by flow infusion analysis of 0.2 g · ml1.
Galindo Bedor et al. Antimicrobial Agents and Chemotherapy
December 2018 Volume 62 Issue 12 e00845-18 aac.asm.org 8
MF  B ⁄ A (4)
Per guidelines from the Brazilian Health Surveillance Agency (ANVISA), the normalized matrix factor








Linearity, precision, and accuracy. Human blood spiked with aliquots of a stock solution of BNZ to
obtain blank samples, zero sample (blank plus IS), and 1 nonzero concentration, 50, 100, 400, 800, 1,500,
3,500, 5,000, 8,000, 12,000, 16,000, or 20,000 ng · ml1, was spotted onto filter paper in order to prepare
three different calibration curves. The linearity was assessed using the WLS method. The acceptance
criteria for each back-calculated standard concentration was 15% deviation from the nominal value,
except at LLOQ, which was set at 20%.
For precision (relative standard deviation) and accuracy (relative error [RE]) studies, four quality
control samples (50, 150, 10,000, and 17,000 ng · ml1) were prepared with nine replicates each and then
analyzed on the same day (for intra-assay precision and accuracy studies) and on three different days
(interassay precision and accuracy studies).
Stability study. For stability studies, quality controls were used at two concentration levels, LQC and
HQC. The samples were processed, along with a fresh standard curve, and concentrations were
determined. The percentage of degradation was obtained by comparing the back calculation of samples
to the nominal value.
Benchtop stability was investigated to ensure that BNZ remained stable in DBS samples at room
temperature for a period sufficient to cover the sample preparation procedure. DBS samples were left at
room temperature (23°C) for 25 h. The samples were then processed and analyzed.
Due to the occasional need for delayed injection or reinjection of extracted samples, the stability of
BNZ in the final solution was also evaluated in the autosampler at 4°C. A group of QC samples of BNZ
was extracted, loaded onto the autosampler, and kept for 25 h before injection.
The following day, the samples were stored in sealed aluminum bags with three desiccant packages
at four temperatures.
FIG 4 Extract ion chromatograms from blanks DBS of BNZ (A) and IS (B), as well as LLOQ of BNZ (C) and IS (D).
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For evaluation of storage stability, the samples were prepared and air dried at 25°C for 3 h and then
stored in sealed aluminum bags with two desiccant packages at room temperature (between 20°C and
26°C) for a period of 466 days. In addition, the samples were prepared and air dried at 40°C for 3 h and
also stored in sealed aluminum bags with two desiccant packages at 40°C for 3 and 7 days. The humidity
during the experiments was 53%.
DBS issues. The whole-blood-spot approach was used for the extraction procedure to avoid any
interference of volume, to maximize the MS/MS signal, and to decrease the influence of hematocrit (26).
An evaluation of hematocrit on the DBS card was carried out. Human blood with EDTA as an
anticoagulant was used to prepare samples at 20%, 30%, 40%, 50%, 60%, and 70% hematocrit. After
centrifugation at 1,300 relative centrifugal force for 20 min, an appropriate volume of serum was added
or removed to adjust the hematocrit (27).
The analyte/IS peak area ratio was compared with the response of DBS QCs at a hematocrit level of
45%, which was used for all validation parameter assessments.
The postcolumn infusion experiment was performed with injection of blank samples at each
hematocrit level. The MS/MS response was monitored to verify the influence of different matrices on the
retention time of analyte and IS.
Pharmacokinetic evaluation and sample collection. Forty-eight healthy volunteers from Brazil (24
men and 24 women) aged 18 to 45 years were included in this study based on their medical history,
physical examination, 12-lead electrocardiography, and laboratory tests (hematology, blood biochemis-
try, hepatic function, and urinalysis) carried out before the study and at its conclusion. Inclusion criteria
were weight within 15% of the ideal body weight, absence of heart, kidney, neurological, or metabolic
diseases, and no history of drug hypersensitivity. Exclusion criteria were abnormal findings on physical
examination, electrocardiography, or laboratory tests, ongoing pharmacological treatment, and history
of alcohol or drug abuse. All subjects signed the consent form approved by the Ethics Committee of the
Federal University of Pernambuco (CAAE; 35626814.0.0000.5208).
The study was an open-label, randomized, two-period, two-treatment, two-sequence, 2-by-2 cross-
over trial, balanced investigation of a single oral dose of BNZ (100-mg tablet) from Laboratório
Farmacêutico da Marinha (Rio de Janeiro, Brazil) and the reference product (from LAFEPE) to evaluate the
relative oral bioavailability of these formulations. Subjects were randomly assigned to one of two groups.
The treatments were administered in the morning with 200 ml water after a 10-h fasting period. No
food was allowed for 3.25 h after ingestion of the dose. Subjects were provided with standard meals:
lunch, a snack, and supper at 3.25 h, 8 h, and 12 h, respectively, after drug administration. The volunteers
did not ingest any food or drink containing caffeine or xanthine during the trial.
Venous blood samples (5 ml) were collected before dosing and at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0,
4.5, 5.0, 6.0, 8.0, 12.0, 23.0, and 47.0 h after dosing.
From these 48 volunteers, three were selected to obtain plasma and DBS samples. Before centrifu-
gation, samples were spotted on Whatman 903 filter paper cards by transferring 50 l blood onto the
card with a volumetric pipette, and the tubes were then submitted to centrifugation for 5 min at 3,000  g.
Plasma samples were stored in polypropylene cryogenic tubes at 80°C until analysis. DBS samples were
allowed to air dry for at least 3 h before being stored.
An evaluation of the relationship between BNZ blood and plasma concentrations was carried out by
Passing-Bablok regression analysis of 40 (approximately 13 from each healthy volunteer) paired samples
of DBS and plasma from the same sample collection, also applying the Bland-Altman approach (32). The
correlation between sampling methods was described using Pearson correlation coefficient (r). All
analyses used MedCalc statistical software, version 18.5 (MedCalc Software bvba, Ostend, Belgium,
http://www.medcalc.org).
The PK parameters for BNZ determined for the plasma and blood matrices were Cmax, time to Cmax
(Tmax), AUC0 –t, AUC0 –∞, kel (elimination rate constant), and t1/2 (elimination half-life). These were calcu-
lated by noncompartmental analysis using Phenix, version 7.0 (Pharsight Corporation, Sunnyvale, CA,
USA). The Cmax and Tmax were obtained directly from the concentration-time curve. The AUC0 –t was
estimated by integration using the log-linear trapezoidal rule from time zero to the last measurable
concentration at time t. kel was calculated through the application of a log-linear regression analysis to
at least the last three quantifiable concentrations of BNZ. t1/2 was calculated as 0.693/kel, and AUC0 –∞ was
calculated as AUC0 –t  Ct/kel, where Ct is the last measurable BNZ concentration.
Additionally, a comparison between PK parameters (bioequivalence) from the Brazilian reference
drug and published data for the Radanil formulation of BNZ (8) was carried out using Phenix, version 7.0
(Pharsight Corporation, Sunnyvale, CA, USA). Predefined bioequivalence parameters were consistent with
FDA guidelines (33).
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